BioNxt Solutions Inc. BNXT
CNSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -77.44% | 77.88% | |||
| Depreciation & Amortization | -37.50% | -75.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -67.97% | 63.16% | |||
| Operating Income | 67.97% | -62.10% | |||
| Income Before Tax | 73.27% | -84.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 73.27% | -100.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 73.27% | -100.97% | |||
| EBIT | 67.97% | -62.10% | |||
| EBITDA | 67.98% | -62.46% | |||
| EPS Basic | 74.09% | -96.03% | |||
| Normalized Basic EPS | 62.07% | -36.47% | |||
| EPS Diluted | 74.09% | -96.03% | |||
| Normalized Diluted EPS | 62.07% | -36.47% | |||
| Average Basic Shares Outstanding | 3.76% | 2.78% | |||
| Average Diluted Shares Outstanding | 3.76% | 2.78% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||